Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Oral and intramuscular methylprednisolone are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]
Marketing Status approved; vet_approved
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 72647-331; 0781-5022; 80425-0230; 59746-003; 59762-0049; 63187-160; 71205-453; 0603-4593; 82094-402; 60722-1003; 64958-0084; 55289-649; 59762-4440; 63629-2218; 68001-557; 68001-560; 80425-0242; 22552-0029; 0009-0056; 45865-104; 59762-0050; 59762-0051; 60760-373; 63187-802; 65162-871; 68071-5221; 70121-1000; 59746-015; 65162-982; 68001-005; 68071-4028; 68084-149; 68788-4593; 71205-054; 72189-264; 82094-401; 45865-417; 50090-3094; 59746-002; 63629-2433; 68001-558; 68180-686; 69306-400; 70518-3622; 82094-403; 59746-001; 68071-2301; 68180-687; 70518-2982; 70771-1348; 70771-1349; 80425-0255; 0009-0073; 49999-153; 53002-3120; 63629-2226; 68001-559; 68180-685; 68180-688; 68382-917; 68382-918; 68382-919; 70771-1350; 80425-0231; 0904-6914; 49452-4686; 51552-0603; 0009-0020; 42806-400; 65162-984; 68180-689; 68382-916; 68788-8276; 69306-004; 70121-1001; 70771-1351; 76420-041; 82298-118; 76420-193; 82094-404; 82094-405; 51927-0201; 0009-0022; 65162-980; 68071-2745; 68788-7833; 0009-0038; 57582-011; 0009-0176; 57582-101
UNII X4W7ZR7023
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye pruritus06.04.05.0060.000070%Not Available
Aerophagia07.01.04.0040.000032%Not Available
Oral pruritus07.05.05.0020.000070%Not Available
Musculoskeletal stiffness15.03.05.0270.000524%Not Available
Epigastric discomfort07.01.02.0040.000032%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000208%Not Available
Injection site swelling08.02.03.017; 12.07.03.0180.000422%Not Available
Bronchopleural fistula22.05.03.0010.000032%
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.007--
Tumour necrosis24.04.02.013; 16.32.03.0090.000032%Not Available
Affect lability19.04.01.0010.000179%Not Available
Scleral thinning06.09.06.004--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000048%Not Available
Phonophobia19.06.03.003; 04.03.01.0080.000032%Not Available
Infusion site reaction12.07.05.006; 08.02.05.0050.000048%Not Available
Haemorrhage24.07.01.002--Not Available
Faecaloma07.01.03.0040.000032%Not Available
Pulmonary mass22.02.07.0040.000032%Not Available
Muscle mass15.05.03.018--Not Available
Pharyngeal erythema22.04.05.0100.000032%Not Available
Pneumatosis intestinalis07.11.01.0430.000032%Not Available
Temperature intolerance08.01.09.0220.000080%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000118%Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Major depression19.15.01.0030.000064%Not Available
Injection site nodule12.07.03.034; 23.07.04.009; 08.02.03.0340.000032%Not Available
Toxic skin eruption12.03.01.073; 10.01.01.008; 23.03.05.0030.000080%Not Available
Metabolic disorder14.11.01.0010.000032%Not Available
Dyslipidaemia14.08.04.0150.000032%Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene